The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.

US-based gene therapy developer Akouos went public on Friday in an initial public offering sized at approximately $213m, scoring exits for pharmaceutical firm Novartis and health system manager Partners HealthCare. The company priced 12.5 million shares at $17.00 each, increasing the number of shares in the offering from 8.3 million and pricing them above the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.